This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kimpimäki, T. Articles by Knip, M. Search for Related Content PubMed PubMed Citation Articles by Kimpimäki, T. Articles by Knip, M.

Disease-Associated Autoantibodies as Surrogate Markers of Type 1 Diabetes in Young Children at Increased Genetic Risk¹

Department of Pediatrics and Tampere Diabetes Research Center, Medical School University of Tampere (T.K., M.K.), and Tampere University Hospital, FIN-33101 Tampere; Department of Pediatrics, University of Oulu (P.K., K.S., P.V.), FIN-90220 Oulu; Turku Immunology Center and Department of Virology, University of Turku (H.R., J.I.), FIN-20520 Turku; and Hospital for Children and Adolescents, University of Helsinki (H.K.Å.), FIN-00290 Helsinki, Finland

Address all correspondence and requests for reprints to: Dr. Mikael Knip, Department of Pediatrics, University of Tampere Medical School, P.O. Box 607, FIN-33101 Tampere, Finland. E-mail: llmikn{at}uta.fi

To evaluate the emergence of diabetes-associated autoantibodies in young children and to assess whether such antibodies can be used as surrogate markers of type 1 diabetes in young subjects at increased genetic risk, we studied 180 initially unaffected siblings (92 boys and 88 girls) of children with newly diagnosed type 1 diabetes. All siblings were younger than 6 yr of age at the initial sampling, and they were monitored for the emergence of islet cell antibodies (ICA), insulin autoantibodies (IAA), glutamate decarboxylase antibodies (GADA), and IA-2 antibodies (IA-2A) up to the age of 6 yr and for progression to clinical type 1 diabetes up to the age of 10 yr. All 160 siblings with DNA samples available were typed for susceptible (DQB1*02 and *0302) and protective (DQB1*0301 and *0602–03) HLA DQB1 alleles. Twenty-two siblings (12.2%) tested positive for ICA in their first antibody-positive sample before the age of 6 yr, 13 (7.2%) tested positive for IAA, 15 (8.3%) tested positive for GADA, and 14 (7.8%) tested positive for IA-2A. There were 16 siblings (8.9%) who had 1 detectable autoantibody, 5 (2.8%) had 2, and 12 (6.7%) had 3 or more. In the group of 82 siblings with increased human leukocyte antigen-defined genetic susceptibility [DQB1*02/*0302, *0302/x (x = other than *02 or a protective allele), *02/y (y = other than *0302 or a protective allele)], 18 (22.0%) tested positive for ICA in their first antibody-positive sample, 10 (12.2%) tested positive for IAA, 14 (17.1%) tested positive for GADA, and 12 (14.6%) tested positive for IA-2A. One antibody was detectable in 6 siblings (7.3%), 2 were detectable in 5 (6.1%), and 3 or more were detectable in 12 (14.6%). Fifteen siblings (18.3%) presented with clinical type 1 diabetes before the age of 10 yr. All of the progressors showed increased human leukocyte antigen-defined genetic susceptibility. Thirteen of those 15 siblings, who presented with clinical type 1 diabetes before the age of 10 yr, had at least 2 antibodies detectable before the age of 6 yr (disease sensitivity, 87%; 95% confidence interval, 60–98%). Thirteen of the 17 siblings who tested positive for 2 or more autoantibodies before the age of 6 yr developed type 1 diabetes before the age of 10 yr (positive predictive value, 76%; 95% confidence interval, 50–93%). These observations suggest that disease-associated autoantibodies can well be used as surrogate markers of clinical type 1 diabetes in primary prevention trials targeting young subjects with increased genetic disease susceptibility.

This article has been cited by other articles:

				M. Knip, R. Veijola, S. M. Virtanen, H. Hyoty, O. Vaarala, and H. K. Akerblom Environmental Triggers and Determinants of Type 1 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S125 - S136. [Abstract] [Full Text] [PDF]

				M. Kukko, T. Kimpimaki, S. Korhonen, A. Kupila, S. Simell, R. Veijola, T. Simell, J. Ilonen, O. Simell, and M. Knip Dynamics of Diabetes-Associated Autoantibodies in Young Children with Human Leukocyte Antigen-Conferred Risk of Type 1 Diabetes Recruited from the General Population J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2712 - 2717. [Abstract] [Full Text] [PDF]

				M. Kukko, S. M. Virtanen, A. Toivonen, S. Simell, S. Korhonen, J. Ilonen, O. Simel, and M. Knip Geographical Variation in Risk HLA-DQB1 Genotypes for Type 1 Diabetes and Signs of {beta}-Cell Autoimmunity in a High-Incidence Country Diabetes Care, March 1, 2004; 27(3): 676 - 681. [Abstract] [Full Text] [PDF]

				S. M Virtanen and M. Knip Nutritional risk predictors of {beta} cell autoimmunity and type 1 diabetes at a young age Am. J. Clinical Nutrition, December 1, 2003; 78(6): 1053 - 1067. [Abstract] [Full Text] [PDF]

				T. Kimpimaki, P. Kulmala, K. Savola, A. Kupila, S. Korhonen, T. Simell, J. Ilonen, O. Simell, and M. Knip Natural History of {beta}-Cell Autoimmunity in Young Children with Increased Genetic Susceptibility to Type 1 Diabetes Recruited from the General Population J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4572 - 4579. [Abstract] [Full Text] [PDF]